Meeting
2022 ASCO Annual Meeting
Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816.
Presenter
Mariano Provencio-Pulla, MD, PhD
Hospital Universitario Puerta de Hierro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02998528
Citation
J Clin Oncol 40, 2022 (suppl 17; abstr LBA8511)
DOI
10.1200/JCO.2022.40.17_suppl.LBA8511
Abstract #
LBA8511
Poster Bd #
138
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Speaker: Jonathan Spicer, FRCPC, MD, PhD
Speaker: Kathi Mooney, PhD, RN
Videos & Slides
2024 ASCO Annual Meeting
Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.
Speaker: Jonathan Spicer, MD, PhD, FRCPC
Videos & Slides
2023 ASCO Annual Meeting
Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.
Speaker: Shun Lu, PhD